ES2097209T3 - Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno. - Google Patents

Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno.

Info

Publication number
ES2097209T3
ES2097209T3 ES91910595T ES91910595T ES2097209T3 ES 2097209 T3 ES2097209 T3 ES 2097209T3 ES 91910595 T ES91910595 T ES 91910595T ES 91910595 T ES91910595 T ES 91910595T ES 2097209 T3 ES2097209 T3 ES 2097209T3
Authority
ES
Spain
Prior art keywords
nalmefene
aid
treatment procedure
alcoholism
alcoholism treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910595T
Other languages
English (en)
Inventor
John D Sinclair
Harry Scheinin
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alko Oy AB
Orion Oyj
Original Assignee
Alko Oy AB
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Oy AB, Orion Yhtyma Oy filed Critical Alko Oy AB
Application granted granted Critical
Publication of ES2097209T3 publication Critical patent/ES2097209T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

UN METODO PARA EL TRATAMIENTO DEL ALCOHOLISMO. SE SUPRIME LA RESPUESTA A LA INGESTION DEL ALCOHOL DE LOS ALCOHOLICOS HACIENDOLES BEBER BEBIDAS ALCOHOLICAS MIENTRAS QUE EL NALMEFENO, UN ANTAGONISTA DEL OPIO, BLOQUEA EL EFECTO DE REFUERZO POSITIVO DEL ETANOL EN EL CEREBRO.
ES91910595T 1990-06-04 1991-05-10 Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno. Expired - Lifetime ES2097209T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (1)

Publication Number Publication Date
ES2097209T3 true ES2097209T3 (es) 1997-04-01

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910595T Expired - Lifetime ES2097209T3 (es) 1990-06-04 1991-05-10 Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno.

Country Status (19)

Country Link
US (1) US5086058A (es)
EP (1) EP0531415B1 (es)
JP (1) JP3059213B2 (es)
AT (1) ATE145329T1 (es)
AU (1) AU642748B2 (es)
CA (1) CA2084519C (es)
DE (1) DE69123247T2 (es)
DK (1) DK0531415T3 (es)
ES (1) ES2097209T3 (es)
FI (1) FI925513L (es)
GR (1) GR3022289T3 (es)
HU (1) HU210637B (es)
IE (1) IE77333B1 (es)
LT (1) LT3893B (es)
LV (1) LV10190B (es)
NZ (1) NZ238391A (es)
RU (1) RU2090190C1 (es)
WO (1) WO1991018605A1 (es)
ZA (1) ZA914185B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
EP1248800A2 (en) * 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
RU2227004C2 (ru) * 2000-06-16 2004-04-20 Писаренко Фаля Юрьевич Способ лечения наркологической зависимости
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
JP4736323B2 (ja) * 2001-07-13 2011-07-27 アークレイ株式会社 分析用具を備えた濃度測定装置用の穿刺要素一体装着体、および体液採取用具
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
RU2215527C2 (ru) * 2001-09-28 2003-11-10 Областная наркологическая больница Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза
RU2200556C1 (ru) * 2001-12-05 2003-03-20 Северцев Владимир Алексеевич Лекарственная форма налтрексона
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
SI2561860T1 (en) * 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
PT1610791E (pt) 2003-03-31 2011-05-23 Titan Pharmaceuticals Inc Dispositivo polim?rico implant?vel para liberta??o sustentada de agonista da dopamina
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US7893080B2 (en) 2006-10-20 2011-02-22 Neurendo Pharma, Llc Method of restoring the incretin effect
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2224808A4 (en) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP5426660B2 (ja) * 2008-04-24 2014-02-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ナルメフェンジ−エステルプロドラッグ
CA2722246C (en) * 2008-04-24 2016-06-21 Janssen Pharmaceutica Nv Nalmefene prodrugs
RU2478388C2 (ru) * 2008-07-07 2013-04-10 Еуро-Селтик С.А. Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
RU2393864C1 (ru) * 2008-12-29 2010-07-10 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и опиоидной наркомании
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP3134090B1 (en) * 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
CN117137917A (zh) * 2016-04-22 2023-12-01 景凯生物科技股份有限公司 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
GR3022289T3 (en) 1997-04-30
EP0531415A1 (en) 1993-03-17
LV10190A (lv) 1994-10-20
HUT65523A (en) 1994-06-28
RU2090190C1 (ru) 1997-09-20
CA2084519C (en) 1999-02-09
HU9203835D0 (en) 1993-03-29
FI925513A7 (fi) 1992-12-04
ZA914185B (en) 1992-07-29
EP0531415B1 (en) 1996-11-20
DE69123247D1 (de) 1997-01-02
DK0531415T3 (da) 1996-12-09
CA2084519A1 (en) 1991-12-05
LTIP1486A (en) 1995-09-25
AU7974091A (en) 1991-12-31
US5086058A (en) 1992-02-04
LV10190B (en) 1995-06-20
JP3059213B2 (ja) 2000-07-04
WO1991018605A1 (en) 1991-12-12
IE77333B1 (en) 1997-12-03
LT3893B (en) 1996-04-25
IE911888A1 (en) 1991-12-04
HU210637B (en) 1995-06-28
FI925513A0 (fi) 1992-12-04
FI925513L (fi) 1992-12-04
ATE145329T1 (de) 1996-12-15
JPH06506665A (ja) 1994-07-28
NZ238391A (en) 1997-06-24
AU642748B2 (en) 1993-10-28
DE69123247T2 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
ES2097209T3 (es) Procedimiento de tratamiento del alcoholismo con la ayuda de nalmefeno.
RU92016403A (ru) Способ лечения алкоголизма налмефеном
ES541988A0 (es) Un procedimiento para rebajar el contenido de alcohol de las bebidas alcoholicas.
TR199501122A2 (tr) Etil alkol üretim yöntemi.
DE59004541D1 (de) Verfahren zum Vermindern des Alkoholgehaltes alkoholischer Getränke.
ES533890A0 (es) Un procedimiento para la separacion de serotonina
FR2741349B1 (fr) Nouveau procede de fabrication du palatinitol
ES2126889T3 (es) Procedimiento de purificacion de eter 1,1,1,3,3,3-hexafluoroisopropilico de fluorometilo.
KR920701418A (ko) 효모 추출물의 제조방법
DE69719382D1 (de) VERFAHREN ZUR HERSTELLUNG VON rDSPA Alpha1
JPS5412304A (en) Purification of polyhydric alcohols
AU2002218231A1 (en) Method for the production of menthalactone
ATE141039T1 (de) Antioxidantienherstellung
JPS5414932A (en) Purification of phenylhydrazine
GB2084607B (en) Method for the production of low alcohol beverages
KR840000885A (ko) 엘더베리(황금포도)음료(음료원액)의 제조방법
DE68918951D1 (de) Verfahren zur herstellung eines mit einer organischen gruppe substituierten natriumaluminiumhydrids.
DK591388D0 (da) Mikrobiologisk fremgangsmaade til fremstilling af polycyclisk-ether-forbindelsen uk-61689 og mikroorganismestammer til anvendelse ved fremgangsmaaden
SU1016283A1 (ru) Способ получени 6-амино-3-метилантрапиридона
ATE263750T1 (de) Neues verfahren
GEP20063918B (en) Method for the production of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrro-lizin-5-ylacetic acid
KR900009684A (ko) β-시토스테롤의 제조방법
KR970006288A (ko) 재결정화 방법을 통한 고순도 바비튜르산의 제조방법
ES2012734A6 (es) Procedimiento para la obtencion de alfa-d-gluco-octono-delta-lactona-eno-diol y su sal calcica.
ITTO920255A0 (it) Procedimento per la produzione di un additivo ricco di etere.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 531415

Country of ref document: ES